A Study of Disitamab Vedotin in Subjects With HER2 Expressing Urothelial Carcinoma
Status:
Not yet recruiting
Trial end date:
2025-11-30
Target enrollment:
Participant gender:
Summary
This study is being done to see if a drug called disitamab vedotin works to treat HER2
expressing urothelial cancer. It will also test how safe the drug is for participants.
Participants will have cancer that has spread in the body near where it started (locally
advanced) and cannot be removed (unresectable) or has spread through the body (metastatic).
It will also study what side effects happen when participants get the drug. A side effect is
anything a drug does to your body besides treating the disease.